NCT07771465Phase 3Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Study sponsor: Kardigan, Inc. · KARD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2032-11Estimated
Enrollment · participants332Estimated
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.